Now live: Pro — the full 13F research suite for serious investorsSee pricing →
DC Funds, LP

Q1 2024 · 13F-HR

DC Funds, LPholdings as filed

Filed 2024-05-14 · accession 0001398344-24-009524

$10.3M
Reported value
3
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
89854M101TCRXTSCAN THERAPEUTICS INC$5.0M48.3%630,000CommonSOLE
95075A107HOWLWEREWOLF THERAPEUTICS INC$3.8M36.9%589,102CommonSOLE
91864C107BRNSBARINTHUS BIOTHERAPEUTICS PL$1.5M14.8%642,204CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.